BD unveils fully automated molecular diagnostics platform in the U.S.
American medical technology company BD (Becton, Dickinson & Company) has reportedly announced the launch of a new fully automated, high-throughput platform in the U.S. catering to infectious disease molecular diagnostics.
The first test available on the new BD COR™ MX